Results for common terminology criteria for... translation from English to Slovenian

nci common terminology criteria for adverse events
merila nci za poenoteno terminologijo neželenih dogodkov (national cancer institute common terminology criteria for adverse events)

worst national cancer institute common terminology criteria for adverse events grade.
a najvišja stopnja po dokumentu skupni terminološki kriteriji za neželene dogodke (common terminology criteria for adverse events, ctcae) nacionalnega onkološkega inštituta zda (national cancer institute, nci)

≤ grade 1 (national cancer institute common terminology criteria for adverse events [nci ctcae])
≤ razred 1 (merila pogostih toksičnosti nacionalnega inštituta za rakava obolenja; national cancer institute common terminology criteria for adverse events [nci ctcae])

for adverse events including
neželenih učinkov.

1 nci ctcae v 4.0 = national cancer institute common terminology criteria for adverse events version 4.0
1 nci ctcae v 4.0 = terminološko poenotena merila neželenih učinkov nacionalnega onkološkega inštituta, različica 4.0

adverse events
stranski učinek

cns adverse events
neželeni učinki na centralni živčni sistem

1 grading based on national cancer institute (nci) common terminology criteria for adverse events (ctcae) v3.0
1 stopnje izraženosti so opredeljene skladno s skupnimi terminološkimi kriteriji za neželene dogodke verzija 3.0 (common terminology criteria for adverse events, ctcae) ameriškega onkološkega inštituta (national cancer institute, nci).

adverse events reporting
poročanje o neželenih dogodkih

adverse events(s)
neželeni učinek (učinki)

(a) the intensity of clinical adverse events graded by the common terminology criteria for adverse events v4.0 (ctc-ae).
(a)izrazitost kliničnih neželenih dogodkov je ocenjena po ctc-ae (common terminology criteria for adverse events) v 4.0.

monitored for adverse events related to irinotecan.
cyp3a4.

frequent monitoring for adverse events and toxicity related
dodatek posakonazola med zdravljenjem z atazanavirjem oziroma z atazanavirjem in ritonavirjem je bil povezan s povečanjem plazemske koncentracije bilirubina.

esco would be the common terminology.
klasifikacija esco bi bila skupna terminološka podlaga.

dose modifications should be made if patients experience the following adverse reactions (grades refer to common terminology criteria for adverse events [ctcae 4.0]):
Če se bolnikom pojavijo naslednji neželeni učinki (stopnje so po ctcae 4.0 [common terminology criteria for adverse events]), je treba odmerek prilagoditi.

that the risk for adverse events is higher during induction.
neželene učinke med indukcijo večje.

these patients should be closely monitored for adverse events.
takšne bolnike je treba natančno kontrolirati glede neželenih učinkov.

if a patient experiences an intolerable or severe skin reaction ( grade 3; common terminology criteria for adverse events, ctcae), cetuximab therapy must be interrupted.
Če se pri bolniku pojavi kožna reakcija, ki je ne more prenašati, ali huda kožna reakcija (≥ 3. stopnje po kriterijih common terminology criteria for adverse events; ctcae), morate prekiniti terapijo s cetuksimabom.

a note: the intensity of clinical adverse events graded by the national cancer institute (nci) common terminology criteria for adverse events (ctcae) version 4.0.
a opomba: izrazitost kliničnih neželenih učinkov je ocenjena po terminološko poenotenih kriterijih za neželene dogodke (ctcae - common terminology criteria for adverse events) ameriškega nacionalnega inštituta za raka (nci - national cancer institute), verzija 4.0.

frequent monitoring for adverse events and toxicity related to nsaids is recommended.
med sočasno uporabo vorikonazola je priporočljivo pogosto nadziranje neželenih učinkov in toksičnosti nsaid.